Nocturia Epidemiology Forecast 2025-2034

Nocturia is described as one of the most prevalent and bothersome of all urinary symptoms, affecting about 50 million people in the United States. It is estimated that 1 in 3 adults who are above the age of 30 years makes at least 2 trips to the bathroom every night, with around 70% of these people bothered by such urinary episodes.

Nocturia Epidemiology Forecast Report Coverage

The “Nocturia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of nocturia. It projects the future incidence and prevalence rates of nocturia across various populations. The study covers age and type as major determinants of the nocturia-affected population. The report highlights patterns in the prevalence of nocturia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of nocturia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Nocturia: Disease Overview

Nocturia, also known as nocturnal urinary frequency, is a prevalent condition that causes an individual to wake up during the night to urinate. It is more common in older adults and is found in both genders. Nocturia is classified into three types: nocturnal polyuria (or overproduction), bladder storage problems, and mixed nocturia. Common symptoms of nocturia include waking up twice or more to urinate during the night, fatigue and sleepiness during the day, and urinating more in volume if polyuria is present.

Nocturia: Treatment Overview

Depending on the underlying cause, nocturia can be treated with a combination of lifestyle changes and medications such as desmopressin or diuretics, if necessary. Desmopressin is often used to treat nocturia linked with nocturnal polyuria. Anticholinergics help in reducing the urge to urinate by relaxing the bladder muscles. Beta-3 adrenergic agonists, including mirabegron, are taken to reduce symptoms of overactive bladder.

Epidemiology

The nocturia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for nocturia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for nocturia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Nocturia is estimated to affect around 1 in 3 individuals who are older than 30. It occurs more frequently in males after 50 whereas before 50, the condition is more common in females.
• Around 50% of adults over 65 wake up at least once during the night to use the bathroom for urination, and nearly 24% have to get up two or more times each night.
• In Europe, an estimated 40 million adults regularly experience sleep disruption due to the need to pass urine at night.
• In a multicenter retrospective study conducted on 875 eligible Japanese patients with nocturia, it was found that nocturnal polyuria was present in 590 patients (67.4%). The prevalence of nocturnal polyuria was 66.6% in men and 70.0% in women.

Country-wise Nocturia Epidemiology

The nocturia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of nocturia varies significantly between countries due to differences in the prevalence of underlying conditions (diabetes, hypertension, obesity, prostate disease, urinary tract infections, and sleep apnea), lifestyle factors, healthcare access, and sociocultural factors. In the United States, 50 million people are affected by nocturia.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of nocturia based on several factors.
• The Nocturia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of nocturia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of nocturia epidemiology in the 8 major markets?
• What will be the total number of patients with nocturia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of nocturia in the 8 major markets in the historical period?
• Which country will have the highest number of nocturia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of nocturia during the forecast period of 2025-2034?
• What are the currently available treatments for nocturia?
• What are the disease risks, signs, symptoms, and unmet needs of nocturia?

This product will be delivered within 3-5 business days.